GlaxoSmithKline, Astellas, AbbVie and Novartis are among the investors in a $40m series B round for the cancer treatment developer.
US-based biopharmaceutical company Effector Therapeutics secured $40m in series B round on Tuesday featuring pharmaceutical firms GlaxoSmithKline (GSK), AbbVie, Astellas and Novartis.
GSK, AbbVie, Astellas and Novartis invested through their respective corporate venturing subsidiaries SR One, AbbVie Biotech Ventures, Astellas Ventures and Novartis Ventures.
The round was led by Altitude Life Science Ventures and also included Abingworth, BioMed Ventures, Column Group, US Venture Partners, Osage University Partners and Mission Bay Capital.
Effector is developing treatments for various types of cancer,…
